Vogenx, Inc.

Chart & performance

D1W1MN

P/E

—

P/S

—

EPS

Div yield, %

—

Shrs. gr., 5y

—

Rev. gr., 5y

Revenues

Net income

CFO

Notes

No notes on this company yet

Write a private note on this company, for your eyes only

Add note

Profile

Vogenx is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapeutics for the treatment of serious diseases associated with dysfunctions in human metabolism, including post-bariatric hypoglycemia (PBH) and gastroparesis. The company's lead product candidate is mizagliflozin, an orally administered, small molecule drug candidate being developed for the treatment of PBH, gastroparesis, and GIP-dependent Cushing's Syndrome.

URL

https://vogenx.com

IPO date

Employees

Domiciled in

Incorporated in

Valuation

No data to show